Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitor (ICI) plus anlotinib as third-line treatment in extensive-stage small cell lung cancer (ES-SCLC). Methods A total of 120 patients with ES-SCLC
Autor:
Eiji Takeuchi, Hisanori Machida, Naoki Kadota, Tsutomu Shinohara, Keishi Naruse, Yoshio Okano, Nobuo Hatakeyama, Yoshihiro Kondou, Katsuhiro Atagi
Publikováno v:
Cancer Immunology, Immunotherapy
Objective Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our stud
Autor:
Bijan Zomorodbakhsch, Jutta Hübner, Andreas Hochhaus, Matthias Rengsberger, Tobias Rachow, Thomas Ernst, Michael Hartmann, Clemens P J G Wolf, Susan Foller
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The aim of our study was to analyse the frequency and severity of different types of potential interactions in oncological outpatients’ therapy. Therefore, medications, food and substances in terms of complementary and alternative medicine
Autor:
Naozumi Harada, Katsunori Uchida, Takeshi Sasaki, Yoshiki Sugimura, Yasutaka Tono, Gill A Webster, Naoyuki Katayama, Shinichi Kageyama, Hiroshi Shiku, Toshiro Mizuno, Yoshihiro Miyahara, Hideki Kanda, Mikiya Ishihara, Eiichi Sato, Taizo Shiraishi, Yasuhide Hori, Norihito Soga, Hiroaki Ikeda, Daisuke Muraoka
Publikováno v:
Cancer Immunology, Immunotherapy
Cholesteryl pullulan (CHP) is a novel antigen delivery system. CHP and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen complexes (CHP-NY-ESO-1) present multiple epitope peptides to the MHC class I and II pathways. Adjuvants are essen
Autor:
Johan Hansson, Rolf Kiessling, Yago Pico de Coaña, Felix-Lennart Fennemann, Roeltje Maas, Maria Wolodarski, Jeroen Melief
Publikováno v:
Cancer Immunology, Immunotherapy
The efficacy of immunotherapies for malignant melanoma is severely hampered by local and systemic immunosuppression mediated by myeloid-derived suppressor cells (MDSC). Inhibitor of differentiation 1 (ID1) is a transcriptional regulator that was show
Autor:
Céleste Lebbé, Andrew S. Brohl, Meliessa H. Hennessy, Michele Milella, Patrick Terheyden, Kent C. Shih, Paul Nghiem, Isaac Brownell, Gerald P. Linette, Karl D. Lewis, Shailender Bhatia, Murtuza Bharmal, Omid Hamid, Michael Schlichting, Sandra P. D'Angelo, Janice M. Mehnert, Matthias Hunger
Publikováno v:
Cancer Immunology, Immunotherapy
Background Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective respon
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Efficacy and the frequency of tumor cavitation have not been investigated in patients with metastatic colorectal cancer (mCRC) and lung metastases (LMs) treated with chemotherapy in combination with bevacizumab. This study was aimed to evalua
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose An integrated population pharmacokinetic (popPK) model was developed to describe the pharmacokinetics (PK) of tyrosine kinase inhibitor cabozantinib in healthy volunteers (HVs) and patients with various cancer types and to identify any differ
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. The objective of this study was to develop a
Autor:
Archana Chaudhary, David Smith, Ling Gao, Laura Q.M. Chow, Ding Wang, Antoinette R. Tan, Crystal S. Denlinger, Yong Lin, Dale R. Shepard
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose The objective of this phase II study was to evaluate pharmacokinetic interaction potential between ramucirumab and paclitaxel in patients with advanced cancer. Methods This study was designed to assess 2-way pharmacokinetic drug–drug intera